FR3132146B1 - Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition - Google Patents

Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition

Info

Publication number
FR3132146B1
FR3132146B1 FR2200690A FR2200690A FR3132146B1 FR 3132146 B1 FR3132146 B1 FR 3132146B1 FR 2200690 A FR2200690 A FR 2200690A FR 2200690 A FR2200690 A FR 2200690A FR 3132146 B1 FR3132146 B1 FR 3132146B1
Authority
FR
France
Prior art keywords
composition
vaccine potential
evaluating
human model
vivo human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2200690A
Other languages
English (en)
Other versions
FR3132146A1 (fr
Inventor
Manon Scholaert
Nicolas Gaudenzio
Emeline Pages
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genoskin SAS
Original Assignee
Genoskin SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoskin SAS filed Critical Genoskin SAS
Priority to FR2200690A priority Critical patent/FR3132146B1/fr
Priority to CA3248735A priority patent/CA3248735A1/fr
Priority to PCT/EP2023/052096 priority patent/WO2023144355A1/fr
Priority to EP23702007.8A priority patent/EP4469797A1/fr
Publication of FR3132146A1 publication Critical patent/FR3132146A1/fr
Priority to US18/785,910 priority patent/US20240410878A1/en
Application granted granted Critical
Publication of FR3132146B1 publication Critical patent/FR3132146B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé in vitro destiné à déterminer le potentiel vaccinal d’une composition comprenant les étapes de: ia) administration transcutanée de la composition à un explant de peau, comprenant l’épiderme, le derme et les annexes épidermiques ainsi qu’une épaisseur d’au moins 5 millimètres d’hypoderme ; ib) du statut d’activation des cellules présentatrices de l’antigène au sein de l’explant de peau ; etii) détermination du potentiel vaccinal de la composition.
FR2200690A 2022-01-27 2022-01-27 Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition Active FR3132146B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2200690A FR3132146B1 (fr) 2022-01-27 2022-01-27 Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition
CA3248735A CA3248735A1 (fr) 2022-01-27 2023-01-27 Ex vivo human model designed to evaluate the vaccine potential of a composition
PCT/EP2023/052096 WO2023144355A1 (fr) 2022-01-27 2023-01-27 Modèle humain ex vivo destiné à l'évaluation du potentiel vaccinal d'une composition
EP23702007.8A EP4469797A1 (fr) 2022-01-27 2023-01-27 Modèle humain ex vivo destiné à l'évaluation du potentiel vaccinal d'une composition
US18/785,910 US20240410878A1 (en) 2022-01-27 2024-07-26 Ex vivo human model intended for evaluating the vaccine potential of a composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2200690A FR3132146B1 (fr) 2022-01-27 2022-01-27 Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition
FR2200690 2022-01-27

Publications (2)

Publication Number Publication Date
FR3132146A1 FR3132146A1 (fr) 2023-07-28
FR3132146B1 true FR3132146B1 (fr) 2025-10-31

Family

ID=82594883

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2200690A Active FR3132146B1 (fr) 2022-01-27 2022-01-27 Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition

Country Status (5)

Country Link
US (1) US20240410878A1 (fr)
EP (1) EP4469797A1 (fr)
CA (1) CA3248735A1 (fr)
FR (1) FR3132146B1 (fr)
WO (1) WO2023144355A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862440A (en) 1972-09-14 1975-01-21 Tokyo Shibaura Electric Co Pulse transforming circuit arrangements using a clock pulse responsive delayed inverter means
FR2833271B1 (fr) * 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
JPWO2005007839A1 (ja) * 2003-07-22 2006-08-31 麒麟麦酒株式会社 ノッチリガンドＤｅｌｔａ−１、ＧＭ−ＣＳＦ、ＴＧＦ−βを用いたヒト末梢血単核球であるＣＤ１４陽性細胞からのランゲルハンス細胞の調製方法
FR2887457B1 (fr) * 2005-06-23 2007-10-05 Fond Bettencourt Schueller Vaccination par ciblage transcutane
WO2007031273A2 (fr) * 2005-09-16 2007-03-22 Universität Bern Equivalents epidermiques artificiels a immunite reconstituee
FR2905380B1 (fr) * 2006-09-04 2008-12-05 Engelhard Lyon Sa Procede de production de cellules de langerhans et/ou de cellules de dentritiques interstitielles/dermiques a partir de monocytes cd14+
EP2207031A1 (fr) * 2009-05-18 2010-07-14 Abbott Biologicals B.V. Test d'adjuvant pour les préparations de vaccins
FR2990106B1 (fr) 2012-05-03 2014-05-09 Genoskin Systeme permettant la maintenance en survie et le transport de biospsies de peau et ses applications
FR3078541B1 (fr) 2018-03-05 2022-07-08 Genoskin Modele d’injection sous-cutanee ex vivo
KR20210034733A (ko) * 2019-09-20 2021-03-31 주식회사 필메카 동물실험 대체를 위한 3차원 인공 조직 및 모니터링 세포의 공동배양 시스템 및 이의 제조방법
EP3940058A1 (fr) * 2020-07-16 2022-01-19 Genoskin Système microfluidique pour contrôler la perfusion, la diffusion et la collecte de molécules sur de longues périodes dans un modèle de peau ex-vivo

Also Published As

Publication number Publication date
WO2023144355A1 (fr) 2023-08-03
CA3248735A1 (fr) 2023-08-03
US20240410878A1 (en) 2024-12-12
FR3132146A1 (fr) 2023-07-28
EP4469797A1 (fr) 2024-12-04

Similar Documents

Publication Publication Date Title
AU2011338530B2 (en) Methods for treating baldness and promoting hair growth
CA3067694C (fr) Reseau de micro-aiguilles pour levres
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
WO2001032129A3 (fr) Augmentation et reparation des imperfections des tissus mous lies a l'age
IL168745A0 (en) Compositions comprising botulinum toxin and a human serum albumin, method for producing the same and use thereof in the preparation of medicaments
HUP0400371A2 (hu) Szén-monoxid alkalmazása szerv átültetés utáni túlélésének vagy működésének javítására alkalmas gyógyszerkészítmény előállítására
JP2013540150A (ja) 発毛を促進又は増強するためのエキソソームの使用
TR200101673A2 (tr) Düz kas hücrelerinin sıkışmasıyla ilgili hastalıkların tedavisindeki kompozisyonlar için biyokimyasal maddeler.
MX2022006547A (es) Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
TW201919664A (zh) 性功能障礙之處理與性生活品質之改良
AR050148A1 (es) Implante y metodo para aumentar y mejorar tejidos
BR0312365A (pt) Meio de cultura autólogo de células-mães progenitoras autólogas humanas, métodos para a preparação do mesmo e de uma composição de células-mães progenitoras autólogas humanas e para a obtenção de células-mães progenitoras musculares autólogas humanas, emprego de um meio de cultura autólogo de células-mães progenitoras autólogas humanas, procedimento para a obtenção de células-mães progenitoras musculares autólogas humanas e procedimento terapêutico de cardiomioplastia celular autóloga, composição enriquecida com células-mães progenitoras musculares autólogas humanas e composição farmacêutica
AU2015225914A1 (en) Microneedle based cell delivery
DE602005009862D1 (de) Verfahren zur herstellung eines papillengewebes der haut mit haarfollikelinduktionspotential
FR3132146B1 (fr) Modèle humain ex vivo destiné à l’évaluation du potentiel vaccinal d’une composition
KR101880776B1 (ko) 육모제 조성물
BRPI0716107A2 (pt) mÉtodos para preparar cÉlulas de langerhans ou cÉlulas dendrÍticas e para diferenciar monàcitos, modelo de cÉlulas, monàcitos cd14+ congelados, uso de pelo menos um modelo de cÉlula e/ou de pelo menos um modelo de tecido, e, mÉtodos para produzir um modelo de tecido, e uma pele reconstruÍda ou uma mucosa reconstruÍda
FR3123125B1 (fr) Modèle humain ex vivo destiné à l’évaluation du potentiel inflammatoire de type allergique ou pseudo-allergique
KR100918473B1 (ko) 공액 리놀레산을 포함하는 미용 시트
CN2507408Y (zh) 微创根治腋臭手术分离器
EP3377124B1 (fr) Procédé de fabrication d'un équivalent de peau et son utilisation pour des essais in vitro et des greffes in vivo
EA200701598A1 (ru) Способ и композиция для восстановления эпителиальных и других клеток и тканей
CN119837822A (zh) 一种基于蛋白载体的活性成分毛囊透皮递送系统
CN211934422U (zh) 一种面部提升设备
JP2016150919A (ja) 塗布用化粧品組成物

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230728

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5